NasdaqGS:TRIB

Stock Analysis Report

Executive Summary

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe.

Snowflake

Fundamentals

Fair value with mediocre balance sheet.

Risks

  • Trinity Biotech has significant price volatility in the past 3 months.
  • Trinity Biotech is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Trinity Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

36.3%

NasdaqGS:TRIB

-0.9%

US Medical Equipment

0.6%

US Market


1 Year Return

-47.8%

NasdaqGS:TRIB

13.5%

US Medical Equipment

4.1%

US Market

TRIB underperformed the Medical Equipment industry which returned 15.5% over the past year.

TRIB underperformed the Market in United States of America which returned 4.7% over the past year.


Share holder returns

TRIBIndustryMarket
7 Day36.3%-0.9%0.6%
30 Day41.9%2.4%3.8%
90 Day-9.1%12.5%2.8%
1 Year-47.8%-47.8%14.5%13.5%6.4%4.1%
3 Year-75.9%-75.9%66.2%60.9%47.0%37.3%
5 Year-88.8%-88.9%128.1%101.0%60.3%42.5%

Price Volatility Vs. Market

How volatile is Trinity Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trinity Biotech undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Trinity Biotech's share price is below the future cash flow value, and at a moderate discount (> 20%).

Trinity Biotech's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Trinity Biotech is loss making, we can't compare its value to the US Medical Equipment industry average.

Trinity Biotech is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Trinity Biotech, we can't assess if its growth is good value.


Price Based on Value of Assets

Trinity Biotech is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Trinity Biotech expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

6.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Trinity Biotech's revenue is expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).

Unable to determine if Trinity Biotech is high growth as no earnings estimate data is available.

Trinity Biotech's revenue growth is positive but not above the United States of America market average.

Unable to compare Trinity Biotech's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare Trinity Biotech's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Trinity Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Trinity Biotech performed over the past 5 years?

-55.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Trinity Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Trinity Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Trinity Biotech's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Trinity Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Trinity Biotech has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Trinity Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Trinity Biotech's financial position?


Financial Position Analysis

Trinity Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Trinity Biotech's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Trinity Biotech's level of debt (185.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 185.5% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Trinity Biotech has sufficient cash runway for more than 3 years based on current free cash flow.

Trinity Biotech has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -23% each year.


Next Steps

Dividend

What is Trinity Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Trinity Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Trinity Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Trinity Biotech has not reported any payouts.

Unable to verify if Trinity Biotech's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Trinity Biotech has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Trinity Biotech's salary, the management and board of directors tenure and is there insider trading?

10.7yrs

Average board tenure


CEO

Ronan O’Caoimh (63yo)

10.8yrs

Tenure

US$585,000

Compensation

Mr. Ronan O'Caoimh co-founded Trinity Biotech PLC in June 1992 and has been its Chief Executive Officer since October 2008. Mr. O'Caoimh served as Chief Executive Officer of Trinity Biotech PLC from March  ...


CEO Compensation Analysis

Ronan's remuneration is about average for companies of similar size in United States of America.

Ronan's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

10.7yrs

Average Tenure

64yo

Average Age

The average tenure for the Trinity Biotech board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Ronan O’Caoimh (63yo)

    Co-Founder

    • Tenure: 10.8yrs
    • Compensation: $585.00k
  • Jim Walsh (61yo)

    Executive Director

    • Compensation: $9.00k
  • Kevin Tansley (48yo)

    CFO, Company Secretary & Executive Director

    • Tenure: 11.7yrs
    • Compensation: $523.00k

Board Members

  • Clint Severson (71yo)

    Non-Executive Director

    • Tenure: 10.7yrs
    • Compensation: $75.00k
  • Denis Burger (75yo)

    Non-Executive Director & Lead Director

  • Ronan O’Caoimh (63yo)

    Co-Founder

    • Tenure: 24.2yrs
    • Compensation: $585.00k
  • Jim Walsh (61yo)

    Executive Director

    • Tenure: 12.5yrs
    • Compensation: $9.00k
  • Jim Merselis (65yo)

    Non-Executive Director

    • Tenure: 10.4yrs
    • Compensation: $75.00k
  • Kevin Tansley (48yo)

    CFO, Company Secretary & Executive Director

    • Tenure: 2.8yrs
    • Compensation: $523.00k

Company Information

Trinity Biotech plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trinity Biotech plc
  • Ticker: TRIB
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: health care equipment
  • Sector: healthcare
  • Market Cap: US$54.135m
  • Shares outstanding: 20.90m
  • Website: Click here

Number of Employees


Location

  • Trinity Biotech plc
  • IDA Business Park
  • Bray
  • Co. Wicklow
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRIBNasdaqGS (Nasdaq Global Select)YesADR EACH REPR 4 CLS'A'ORD USD0.019USUSDOct 1992
TRBADB (Deutsche Boerse AG)YesADR EACH REPR 4 CLS'A'ORD USD0.019DEEUROct 1992

Biography

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Afr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/16 23:43
End of Day Share Price2019/07/16 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.